NEW YORK, Sept. 5 Forest Laboratories, Inc.(NYSE: FRX) and H. Lundbeck A/S of Denmark said today that the U.S. Court ofAppeals for the Federal Circuit has affirmed a July 13, 2006 decision by theU.S. District Court for the District of Delaware which determined that theU.S. patent covering escitalopram, the active ingredient in Lexapro(R), isvalid and upheld the injunction preventing Ivax/Teva's proposed genericproduct launch, thereby confirming Forest's and Lundbeck's patent rights forLexapro(R), which expire in March 2012.
(Logo: http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGO )
The patent at issue in the U.S. lawsuit is Lexapro's patent (U.S. PatentNo. Re 34,712), which is set to expire in March 2012 and covers substantiallypure escitalopram.
About Forest Laboratories and Its Products
Forest Laboratories (www.frx.com) is a US-based pharmaceutical companydedicated to identifying, developing and delivering products that make apositive difference in peoples' lives. Forest Laboratories' growing productline includes Lexapro(R) (escitalopram oxalate), an SSRI indicated for adultsfor the initial and maintenance treatment of major depressive disorder andgeneralized anxiety disorder; Namenda(R) (memantine HCl), an N-methyl D-aspartate (NMDA)-receptor antagonist indicated for the treatment of moderateto severe Alzheimer's disease; Benicar(R)* (olmesartan medoxomil), anangiotensin receptor blocker, and Benicar* HCT(R) (olmesartan medoxomil-hydrochlorothiazide), an angiotensin receptor blocker and diuretic combinationproduct, each indicated for the treatment of hypertension; and Campral(R)*(acamprosate calcium), indicated in combination with psychosocial support forthe maintenance of abstinence from alcohol in patients with alcohol dependencewho are abstinent at treatment initiation.
*Benicar is a registered trademark of Daiichi Sankyo, Inc., and Campral isa registered trademark of Merck Sante s.a.s., subsidiary of Merck KGaA,Darmstadt, Germany.
Except for the historical information contained herein, this releasecontains "forward-looking statements" within the meaning of the PrivateSecurities Litigation Reform Act of 1995. These statements involve a number ofrisks and uncertainties, including the difficulty of predicting FDA approvals,the acceptance and demand for new pharmaceutical products, the impact ofcompetitive products and pricing, the timely development and launch of newproducts, and the risk factors listed from time to time in the ForestLaboratories' SEC reports, including the Company's Annual Report on Form 10-Kfor the fiscal year ended March 31, 2007 and quarterly report on form 10-Q forthe period ended June 30, 2007.
SOURCE Forest Laboratories, Inc.